Cervical Cancer: All About India’s First Homegrown Vaccine, Its Price, Launch Date, And How Will it Help Prevent Fatal Disease.
India will launch its first-ever self-developed vaccine for the prevention of cervical cancer. The vaccine will be launched in IIC Delhi.
India will launch its first-ever self-developed vaccine for the prevention of cervical cancer. The vaccine will be launched in IIC Delhi by SII CEO Adar Poonawalla along with Jitendra Sigh Union Minister of Science and Technology.
The Serum Institute of India (SII), which developed the country’s first Covid-19 vaccine, has received permission from the Drugs Controller General of India (DCGI) to manufacture an indigenously developed vaccine against cervical cancer.
CERVICAL CANCER: PRICE AND LAUNCH
Despite the fact that this will be India’s first vaccine for cervical cancer prevention, it will be available at an affordable cost. “Scientific efforts at times do not get the scale of recognition they deserve. So this event is to celebrate that scientific completion,” he said. CEO of the Serum Institute of India (SII) Adar Poonawalla, who was also present, told reporters on the sidelines of the event, “The cervical cancer vaccine will be affordable and would be available in the range of Rs 200-400. However, the final price is yet to be decided”.
Poonawalla said the vaccine will be possibly launched by the end of the year. First, the vaccine would be made available through the government channel, and from next year onwards some private partners would be involved too, he said. Poonawalla also said that a plan to make 200 million doses is in place and first the vaccine would be given in India and only after that it will be exported to other countries.
EFFICACY OF CERVICAL CANCER
The vaccine’s specifications and trials have yet to be completed, but the potency of the India-made cervical cancer vaccine is expected to be between 80 and 95 percent, as is the case with most HPV vaccine jabs. According to the officials, the HPV vaccine CERVAVAC has demonstrated a robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups. Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age. The Drugs Controller General of India (DCGI) had in July granted market authorization to the SII to manufacture the vaccine against cervical cancer.